Brief: Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward Ind For (Z)-Endoxifen Clinical Program In Er+/Her2- Metastatic Breast Cancer
29/07/2025 12:46
July 29 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS ANNOUNCES POSITIVE FDA FEEDBACK, ADVANCES TOWARD IND FOR (Z)-ENDOXIFEN CLINICAL PROGRAM IN ER+/HER2- METASTATIC BREAST CANCER Source text: ID:nPn84gZfDa Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary